Skip to content
November 16, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Medical Research and Clinical Trials
  • CG Oncology’s Gene Therapy Shows Remarkable Efficacy in Pivotal NMIBC Trial, Paving Way for Broader Regulatory Submission
  • Medical Research and Clinical Trials

CG Oncology’s Gene Therapy Shows Remarkable Efficacy in Pivotal NMIBC Trial, Paving Way for Broader Regulatory Submission

Reynand Wu November 16, 2026 6 minutes read
cg-oncologys-gene-therapy-shows-remarkable-efficacy-in-pivotal-nmibc-trial-paving-way-for-broader-regulatory-submission

[City, State] – [Date] – CG Oncology, a clinical-stage immuno-oncology company, has announced a significant milestone in its development of cretostimogene grenadenorepvec, an adenovirus-based oncolytic viral immunotherapy. The company has reported a second pivotal trial win, with the PIVOT-006 Phase III trial demonstrating substantial improvements in non-muscle invasive bladder cancer (NMIBC). This success is poised to broaden the company’s Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA), potentially offering a new therapeutic option for a wider patient population suffering from this challenging form of bladder cancer.

The PIVOT-006 trial, registered under NCT06111235, investigated cretostimogene grenadenorepvec in patients diagnosed with intermediate-risk and high-grade Ta, T1 (≤3 cm) NMIBC following complete tumor resection via transurethral bladder tumor resection (TURBT). The study enrolled a substantial 367 patients across approximately 90 clinical sites in both the United States and Canada, underscoring its broad reach and significance.

Following the announcement of these promising data, CG Oncology’s stock experienced a notable surge. On November 16th, the company’s shares opened at $92, a significant increase of 23.7% from the $74.40 closing price on November 13th, reflecting market confidence in the therapy’s potential.

PIVOT-006 Trial: Unveiling a Significant Reduction in Recurrence

The PIVOT-006 trial’s primary objective was to assess the efficacy of cretostimogene grenadenorepvec in preventing cancer recurrence after surgical removal of NMIBC. Patients in the investigational arm received cretostimogene, while the control arm received no intervention post-resection, though they were monitored and offered cretostimogene as an extension arm if recurrence was detected.

The results were compelling. Cretostimogene demonstrated a remarkable 68% reduction in the risk of recurrence compared to the control arm, with a hazard ratio (HR) of 0.32. This statistically significant benefit was observed with a median follow-up of 17 months as of October 26, 2026. This data suggests that cretostimogene may significantly delay or prevent the return of bladder cancer after initial treatment, a critical concern for patients with NMIBC.

Safety Profile: Well-Tolerated and Encouraging

Beyond its efficacy, cretostimogene grenadenorepvec also exhibited a favorable safety profile in the PIVOT-006 trial. The observed safety results were consistent with those reported in previous studies, indicating a generally well-tolerated treatment. Crucially, the study reported no Grade 3 or greater treatment-related adverse events (TRAEs), nor were there any treatment-related discontinuations. This robust safety data is a vital component for regulatory approval and physician adoption, suggesting that the benefits of cretostimogene may outweigh its risks for eligible patients.

Chronology of Development and Regulatory Strategy

CG Oncology’s journey with cretostimogene has been marked by strategic clinical development and proactive engagement with regulatory bodies. The company has pursued a two-pronged approach, initially focusing on BCG-unresponsive NMIBC and now expanding its sights to intermediate-risk and high-grade Ta NMIBC.

The company’s original BLA submission was planned to focus on patients with BCG-unresponsive NMIBC, specifically those with carcinoma in situ (CIS) with or without papillary tumors, and high-grade papillary-only disease. This initial application was to be supported by data from the pivotal BOND-003 trial (NCT04452591).

CG Oncology’s stock up as gene therapy gains second win in NMIBC

The success of the PIVOT-006 trial now allows CG Oncology to pursue a broadened BLA. Based on the strong PIVOT-006 data and prior feedback from the U.S. Food and Drug Administration (FDA), the company is aiming to submit this expanded application in the second quarter of 2027. This broadened submission will encompass not only BCG-unresponsive NMIBC but also intermediate-risk and high-grade Ta NMIBC, significantly expanding the potential patient population eligible for cretostimogene.

Cretostimogene grenadenorepvec is an investigational, intravesically delivered oncolytic immunotherapy. Its development has already garnered attention from the FDA, as evidenced by its previous designation as a Fast Track and Breakthrough Therapy for BCG-unresponsive NMIBC. These designations highlight the unmet medical need and the potential of cretostimogene to address it.

Supporting Data and Market Context

The promising results from PIVOT-006 are set against a backdrop of increasing innovation and market growth in the bladder cancer landscape. The bladder cancer market, encompassing both NMIBC and muscle-invasive bladder cancer (MIBC), is projected to experience substantial growth. According to a report by GlobalData, the parent company of Clinical Trials Arena, this market is expected to expand from $3 billion in 2023 to an impressive $16 billion by 2033, representing a compound annual growth rate (CAGR) of 18%. This growth is attributed to several factors, including an increasing incidence of bladder cancer and a wave of therapeutic advancements across both NMIBC and MIBC segments.

The therapeutic landscape for NMIBC is rapidly evolving. CG Oncology is not alone in reporting positive developments. Other companies are also making strides in this area. For instance, enGene has reported a 62% complete response (CR) rate in its Phase III trial of detalimogene voraplasmid, another investigational intravesical gene therapy, after six months of treatment. Furthermore, UroGen has secured approval for Zusduri (mitomycin) for low-grade, intermediate-risk NMIBC. The presence of multiple promising therapies in development, including drugs like MSD’s Keytruda, which are in Phase III trials, indicates a transformative period for bladder cancer treatment.

Official Responses and Future Implications

The significance of the PIVOT-006 trial results was underscored by the enthusiastic response from CG Oncology’s leadership. Arthur Kuan, Chairman and CEO of CG Oncology, stated, “The unparalleled PIVOT-006 results represent a defining milestone for CG Oncology and position cretostimogene as the first and only therapeutic candidate to demonstrate a significant recurrence benefit in a pivotal Phase III trial in intermediate-risk and HG Ta NMIBC.” This statement highlights the groundbreaking nature of the findings and the potential for cretostimogene to become a cornerstone therapy in NMIBC treatment.

The implications of these trial results are far-reaching. The successful demonstration of efficacy and safety in PIVOT-006, coupled with the impending broadened BLA submission, positions CG Oncology to potentially capture a larger share of the rapidly growing bladder cancer market. The ability to offer a novel, intravesical oncolytic immunotherapy to a wider patient population, including those with intermediate-risk NMIBC who may not be eligible for or responsive to current treatments, represents a significant advancement in patient care.

Analysts are closely watching the NMIBC space, with expectations that the approval of novel intravesical therapies and advancements in other bladder cancer treatment modalities will continue to reshape the market. CG Oncology’s cretostimogene grenadenorepvec is poised to be a key player in this evolving landscape, offering a much-needed therapeutic option and a beacon of hope for patients battling non-muscle invasive bladder cancer. The company’s strategic progression from initial BLA planning to a broadened submission based on robust Phase III data demonstrates a clear path towards potentially bringing this innovative therapy to patients in need.

About the Author

Reynand Wu

Author

View All Posts

Post navigation

Previous: Nourishing the Fight: How Real Food Can Empower Breast Cancer Patients and Survivors to Combat Inflammation

Related Stories

a-paradigm-shift-in-cancer-immunotherapy-mount-sinai-scientists-target-tumor-protectors-not-just-the-tumors-themselves
  • Medical Research and Clinical Trials

A Paradigm Shift in Cancer Immunotherapy: Mount Sinai Scientists Target Tumor Protectors, Not Just the Tumors Themselves

Dwi Wanna November 16, 2026
aclaris-therapeutics-bosakitug-fails-to-meet-primary-endpoints-in-atopic-dermatitis-phase-ii-trial-shifting-focus-to-oral-kinase-inhibitors
  • Medical Research and Clinical Trials

Aclaris Therapeutics’ Bosakitug Fails to Meet Primary Endpoints in Atopic Dermatitis Phase II Trial, Shifting Focus to Oral Kinase Inhibitors

Asep Darmawan November 16, 2026
unraveling-the-colorectal-cancer-paradox-a-new-era-for-immunotherapy-emerges-from-msk-research
  • Medical Research and Clinical Trials

Unraveling the Colorectal Cancer Paradox: A New Era for Immunotherapy Emerges from MSK Research

Nila Kartika Wati November 16, 2026

Recent Posts

  • CG Oncology’s Gene Therapy Shows Remarkable Efficacy in Pivotal NMIBC Trial, Paving Way for Broader Regulatory Submission
  • Nourishing the Fight: How Real Food Can Empower Breast Cancer Patients and Survivors to Combat Inflammation
  • The Algorithmic Frontier: How Artificial Intelligence is Redefining Breast Cancer Risk and Health Equity
  • FDA Mandates Vision Warning for GLP-1 Receptor Agonists Amid Scientific Debate and Litigation
  • Beyond the Results: The Essential Role of Genetic Counsellors in Modern Healthcare

Recent Comments

No comments to show.

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

cg-oncologys-gene-therapy-shows-remarkable-efficacy-in-pivotal-nmibc-trial-paving-way-for-broader-regulatory-submission
  • Medical Research and Clinical Trials

CG Oncology’s Gene Therapy Shows Remarkable Efficacy in Pivotal NMIBC Trial, Paving Way for Broader Regulatory Submission

Reynand Wu November 16, 2026
nourishing-the-fight-how-real-food-can-empower-breast-cancer-patients-and-survivors-to-combat-inflammation
  • Patient Advocacy and Support

Nourishing the Fight: How Real Food Can Empower Breast Cancer Patients and Survivors to Combat Inflammation

Evan Lee Salim November 16, 2026
A female doctor sits at her desk and talks to a female patient while looking at her mamogram. Brest cancer
  • Patient Advocacy and Support

The Algorithmic Frontier: How Artificial Intelligence is Redefining Breast Cancer Risk and Health Equity

Raul Delapena Setiawan November 16, 2026
fda-mandates-vision-warning-for-glp-1-receptor-agonists-amid-scientific-debate-and-litigation
  • Treatment Innovations

FDA Mandates Vision Warning for GLP-1 Receptor Agonists Amid Scientific Debate and Litigation

Reynand Wu November 16, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.